Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.

Herens, Christian; Baron, Frédéric; Croisiau, Christiane; Tassin, Françoise; Bours, Vincent

doi:10.1016/S0165-4608(03)00198-5

Article (Scientific journals)

Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.

Herens, Christian; Baron, Frédéric; Croisiau, Christiane et al.

2003 • In Cancer Genetics and Cytogenetics, 147 (1), p. 78-80

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/12976

DOI
10.1016/S0165-4608(03)00198-5

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

tassin clonal chromosome.pdf

Publisher postprint (76.83 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Antineoplastic Agents/therapeutic use; Chromosome Aberrations; Chromosome Deletion; Chromosome Mapping; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/genetics; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/drug therapy/genetics; Male; Middle Aged; Piperazines/therapeutic use; Pyrimidines/therapeutic use

Abstract :

[en] Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal chromosomal aberrations in Philadelphia-negative (Ph-) cells during treatment has been reported. We describe two CML patients in chronic phase who presented with complete cytogenetic responses during imatinib mesylate therapy but developed new clonal chromosomal rearrangements in Ph- cells. The first patient presented with a duplication of chromosome 1, dup(1)(q21q42), and the second showed two new clonal aberrations consisting of inv(1)(q12q32) and del(7)(q22) in the same clone.

Disciplines :

Genetics & genetic processes

Author, co-author :

Herens, Christian ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Croisiau, Christiane

Tassin, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie

Bours, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Language :

English

Title :

Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.

Publication date :

2003

Journal title :

Cancer Genetics and Cytogenetics

ISSN :

0165-4608

eISSN :

1873-4456

Publisher :

Elsevier Science, New York, United States - New York

Volume :

147

Issue :

Pages :

78-80

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 20 May 2009

Statistics

Number of views

121 (12 by ULiège)

Number of downloads

6 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 43:1973;290-293.
Sawyers C.L. Chronic myeloid leukemia. N Engl J Med. 340:1999;1330-1340.
Druker B.J., Talpaz M., Resta D.J., Bin Peng R.N., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
Marktel S., Bua M., Marin D., Chase A., Udom C., Armstrong L., Apperley J.F., Olavarria E., Goldman J.M. Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. [abstract] Blood. 98:2001;617a.
Gambacorti-Passeri C., Giudici G., Le Coutre P., Bungaro S., Pogliani E.M., Kreuzer K.-A., Tornaghi L., Alberti D., Corneo G., Biondi A. Nonrandom chromosomal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic responses (MCR) with STI571 (Gleevec™). [abstract] Blood. 98:2001;257b.
Meunier V., Giraudier S., Van den Akker J., Perot C., Jouault H., Caron-Servan B., Robin V., Tulliez M., Imbert M. Treatment with STI571 (Novartis) in chronic myeloid leukemia (CML): unexpected hematological findings in a series of 26 patients. [abstract] Blood. 98:2001;263b.
Andersen M.K., Pedersen-Bjergaard, Kjeldsen L., Dufva I.H., Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 16:2002;1390-1395. [letter].
Braziel R.M., Launder T.M., Druker B.J., Olson S.B., Magenis R.E., Mauro M.J., Sawyers C.L., Paquette R.L., O'Dwyer M.E. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 month's experience. Blood. 200:2002;435-441.
Casali M., Truglio F., Milone G., Raimondo F., Parrinello G., Maserati E., Pasquali F. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer. 4:1992;269-270.
Bilhou-Nabera C., Marit G., Devianne I., Viard F., Salzes S., Montastruc M., Renoux M., Broustet A., Reiffers J., Bernard P. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer. 4:1993;255-256.
Ariyama T., Inazawa J., Uemura Y., Kakazu N., Maekawa T., Urase F., Irimajiri K., Horiuchi A., Nakamura Y., Abe T. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet. 81:1995;20-23.
Ohtsuka E., Kikuchi H., Abe Y., Moriyama K., Ohno E., Hirota K., Tezono K., Nasu M. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome. Br J Cancer. 90:1995;951-953.
Izumi T., Imagawa S., Hatake K., Miura Y., Ariyama T., Inazawa J., Abe T. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Int J Hematol. 64:1996;73-77.
Fayad L., Kantarjian H., O'Brien S., Seong D., Albitar M., Keating M., Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 11:1997;767-771.